BPC-157 has become a shorthand for faster recovery in peptide culture, with conversation spanning tendons, joints, and the gut.
The FDA review focused on ulcerative colitis and found limited human clinical evidence plus major product-characterization and safety uncertainty.
What a visitor should know.
Technical details: aliases, tracked claims, and data record
5 names in this peptide family.
BPC-157 free base and BPC-157 acetate are tracked as distinct nominated forms; neither is treated as an FDA-approved drug.
4 evidence questions.
Human benefitLimited human evidenceDoes BPC-157 have established human clinical benefit for ulcerative colitis?
FDA approvalNo FDA approval identifiedIs BPC-157 FDA approved?
503A statusRegulatory recordIs BPC-157 on FDA's final 503A Bulks List or generally permitted because of committee activity?
Identity transferIdentity-sensitiveAre every product, alias, form, and related compound labeled BPC-157 automatically interchangeable?
See every BPC-157 evidence question →Open the machine-readable record ↗PCAC gave a favorable advisory recommendation
The committee recommended BPC-157-related bulk drug substances for possible inclusion on the 503A Bulks List.
FDA received advice from its expert compounding committee.
The compound was not FDA-approved, and the vote alone did not add it to the final 503A Bulks List.
How the FDA record developed.
This timeline separates early nominations and scientific reviews from committee votes and final FDA decisions.
PCAC gave a favorable advisory recommendation
The committee recommended BPC-157-related bulk drug substances for possible inclusion on the 503A Bulks List.
Read the source ↗FDA published its scientific briefing
FDA released its evaluation of BPC-157-related bulk drug substances for the committee meeting.
Read the source ↗BPC-157 entered FDA's 503A nomination record
Two organizations nominated BPC-157-related substances for possible use in pharmacy compounding. The nominations were later withdrawn, and FDA continued the evaluation on its own initiative.
Read the source ↗What has actually been studied?
Human studies appear on the left. Animal, cell, and laboratory studies appear on the right because they cannot establish that a treatment works in people.
Limited human clinical evidence for the reviewed use; FDA identified substantial characterization and safety uncertainty.
Read the FDA review ↗Preclinical findings were reviewed separately and do not establish clinical benefit in people.
Read the FDA review ↗BPC-157 was associated with improved healing in a rat intestinal-anastomosis model. This does not establish benefit for tendon injury, recovery, or inflammatory bowel disease in people.
Read the study on PubMed ↗Important unknowns.
- Human safety information is limited for the proposed routes and uses.
- FDA identified uncertainty around active-ingredient characterization, peptide-related impurities, or aggregation.
- Limited evidence of harm should not be interpreted as evidence of safety.
These are evidence and regulatory uncertainties, not an individualized assessment of whether a treatment is appropriate.
Read the original sources.
Technical change history and comparison data
3 dated changes. 3 comparison groups.
These records show what each source added and whether it changed Peplyst's public conclusion.